Beyond Air (XAIR) Stock Price, News & Analysis

Beyond Air, Inc. (NASDAQ: XAIR) is a commercial-stage medical device and biopharmaceutical company that focuses on harnessing endogenous and exogenous nitric oxide (NO) to address serious medical conditions. According to the company’s public disclosures, Beyond Air develops NO generators and delivery systems intended to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors.

The company’s core technology is the LungFit platform, a family of nitric oxide generators and delivery systems capable of producing NO from ambient air. Beyond Air states that the ventilator-compatible version of LungFit can generate NO on demand at concentrations ranging from 1 part per million (ppm) to 80 ppm for delivery to the lungs, and the platform can generate NO up to 400 ppm for certain applications. LungFit systems are designed to deliver NO either continuously or for a fixed amount of time at various flow rates, with the ability to titrate dose on demand or maintain a constant dose.

Main commercial product: LungFit PH

Beyond Air reports that its first commercial system, LungFit PH, has received premarket approval from the U.S. Food and Drug Administration (FDA) and a CE Mark in Europe. The system is indicated for the treatment of term and near-term neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in conjunction with ventilatory support and other appropriate agents. This condition is commonly referred to as persistent pulmonary hypertension of the newborn (PPHN). The company notes that LungFit PH is approved for commercial use in the United States, the European Union, and many other countries around the world.

Beyond Air highlights that LungFit PH generates NO from ambient air and eliminates the need for traditional high‑pressure cylinders. The company states that this tankless approach can reduce inventory and storage requirements in hospitals, remove NO₂ purging steps, and provide operational benefits compared with cylinder-based systems. Public announcements also describe an expanding international distribution network for LungFit PH, with coverage agreements in multiple regions.

Pipeline LungFit systems for severe lung infections

Beyond Air indicates that it is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia (which may include COVID‑19) and nontuberculous mycobacteria (NTM). Company materials explain that LungFit can deliver NO at concentrations at or above 80 ppm for potential use in treating severe acute lung infections in the hospital setting, and chronic, refractory lung infections in the home setting. Beyond Air notes that these higher‑concentration and home‑use applications remain investigational and are not approved for commercial use.

Neonatal and cardiopulmonary indications

Beyond Air’s disclosures describe the medical context for PPHN, a syndrome characterized by elevated pulmonary vascular resistance that leads to hypoxemia due to decreased pulmonary blood flow and right‑to‑left shunting of blood. NO gas is identified as a vasodilator that is approved in numerous countries to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near‑term neonates with hypoxic respiratory failure associated with pulmonary hypertension when used with ventilator support and other appropriate agents. LungFit PH is positioned within this established therapeutic framework as a cylinder‑free NO delivery option.

Beyond Cancer, Ltd. – ultra‑high concentration NO for solid tumors

Beyond Air reports that Beyond Cancer, Ltd., an affiliate of the company, is a development‑stage biopharmaceutical and medical device entity focused on ultra‑high concentration NO (sometimes described as UNO) delivered via a proprietary platform to treat primary tumors and prevent metastatic disease. Public information indicates that nitric oxide at ultra‑high concentrations has been reported to show anticancer properties and potential roles as a chemosensitizer and radiotherapy enhancer. Beyond Cancer is conducting a first‑in‑human study in subjects with solid tumors and preclinical studies in multiple solid tumor models to inform additional treatment protocols.

Company updates describe a Phase 1a monotherapy trial evaluating intratumoral ultra‑high concentration NO in subjects with advanced, relapsed or refractory unresectable cutaneous and subcutaneous solid tumors, and a planned Phase 1b combination trial in patients whose disease has progressed or remained stable after anti‑PD‑1 therapy. These programs remain in early‑stage clinical development.

NeuroNOS and neurological indications

Beyond Air has also disclosed activities in neurology through NeuroNOS, previously described as a majority‑owned or wholly owned subsidiary structure within the corporate group. NeuroNOS focuses on small‑molecule therapeutics that cross the blood‑brain barrier to regulate NO levels in the brain for neurodevelopmental and neurodegenerative disorders. Company and partner communications state that preclinical studies have demonstrated elevated NO levels in children with Autism Spectrum Disorder (ASD) and in adults with certain brain diseases, including brain cancers and Alzheimer’s disease, and that managing NO levels in the brain is considered important for maintaining normal function.

Public filings and press releases note that NeuroNOS has obtained U.S. FDA Orphan Drug Designations for two investigational therapies: BA‑101 for the treatment of glioblastoma (GBM) and BA‑102 for Phelan‑McDermid Syndrome (PMS), a condition associated with ASD. These programs are described as being in preclinical development, with plans to advance toward first‑in‑human clinical trials. In a later transaction, Beyond Air reported entering into an agreement under which XTL Biopharmaceuticals Ltd. agreed to acquire 85% of NeuroNOS, with Beyond Air retaining an economic interest and potential milestone payments.

Autism and broader neurological research collaborations

Beyond Air states that it has partnered with The Hebrew University of Jerusalem to advance a preclinical program dedicated to the treatment of Autism Spectrum Disorder and other neurological disorders. This collaboration supports the broader NO‑modulation research strategy in the central nervous system. Disclosures emphasize a goal of developing disease‑modifying therapeutics that target underlying pathophysiology rather than only symptomatic relief, particularly in ASD‑related indications.

Capital markets activity and financing

As a Nasdaq‑listed company, Beyond Air regularly reports financing transactions and capital structure changes. Public filings describe activities such as private placements of common stock and warrants, inducement exercises of existing warrants, an equity line of credit, and a secured promissory note. For example, the company has announced an agreement for a promissory note and an equity purchase arrangement with Streeterville Capital, as well as a reverse stock split of its common stock at a 1‑for‑20 ratio to meet Nasdaq listing requirements. These transactions are characterized as providing working capital, supporting commercial operations for LungFit PH, and funding clinical and preclinical programs.

Regulatory and quality framework

Beyond Air reports that it has achieved certification demonstrating conformity of its quality management system with the regulatory requirements of countries participating in the Medical Device Single Audit Program (MDSAP), which includes Australia, Brazil, Canada, the European Union, Japan, and the United States. The company has also disclosed the submission of a premarket approval supplement to the FDA for a second‑generation LungFit PH device and has referenced patent protection, including a design patent allowance for this next‑generation system.

Business model and sector classification

Across its disclosures, Beyond Air characterizes itself as both a commercial‑stage medical device company and a biopharmaceutical company. On the device side, the business centers on NO generators and delivery systems, with LungFit PH as the first approved product for neonatal and cardiopulmonary indications and additional LungFit systems in clinical development for severe lung infections. On the biopharmaceutical side, the company and its affiliates pursue NO‑based therapeutics in oncology and neurology, including ultra‑high concentration intratumoral NO and small‑molecule nNOS inhibitors for ASD‑related and brain cancer indications.

In industry classification terms, Beyond Air is associated with the Manufacturing sector and has been categorized under Other Industrial Machinery Manufacturing, reflecting its development and production of specialized medical devices and related technologies.